Lyell Immunopharma Files 8-K on Shareholder Votes

Ticker: LYEL · Form: 8-K · Filed: May 21, 2025 · CIK: 1806952

Lyell Immunopharma, Inc. 8-K Filing Summary
FieldDetail
CompanyLyell Immunopharma, Inc. (LYEL)
Form Type8-K
Filed DateMay 21, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

TL;DR

Lyell Immunopharma held a shareholder vote on May 15th, details filed May 21st.

AI Summary

Lyell Immunopharma, Inc. filed an 8-K on May 21, 2025, reporting on matters submitted to a vote of security holders as of May 15, 2025. The filing details the company's corporate information, including its incorporation in Delaware and principal executive offices in South San Francisco, California.

Why It Matters

This filing indicates that Lyell Immunopharma held a vote of its security holders, which could pertain to significant corporate actions or governance matters.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding a shareholder vote and does not contain information about financial distress or significant operational changes.

Key Players & Entities

  • Lyell Immunopharma, Inc. (company) — Registrant
  • May 15, 2025 (date) — Earliest event reported
  • May 21, 2025 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • South San Francisco, California (location) — Principal executive offices

FAQ

What specific matters were submitted to a vote of Lyell Immunopharma's security holders?

The filing does not specify the exact matters voted upon, only that a submission to a vote of security holders occurred as of May 15, 2025.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on May 15, 2025.

What is Lyell Immunopharma's state of incorporation?

Lyell Immunopharma, Inc. is incorporated in Delaware.

Where are Lyell Immunopharma's principal executive offices located?

Lyell Immunopharma's principal executive offices are located at 201 Haskins Way, South San Francisco, California, 94080.

What is the SEC file number for Lyell Immunopharma?

The SEC file number for Lyell Immunopharma, Inc. is 001-40502.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 21, 2025 regarding Lyell Immunopharma, Inc. (LYEL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.